

SUBJECT INDEX TO VOLUME 71

- Action sequence tasks
 - phasic mesolimbic dopamine signaling as predictor of performance of, 846
- Acute myocardial infarction
 - biomarkers in, 22
 - cognitive depressive symptoms in, 22
- Acute stress
 - hippocampal long-term depression and, 75
- Addiction
 - chronic ethanol exposure
 - delta opioid receptor emergence after, 232
 - nociceptin/orphanin FQ blockade of corticotropin-releasing factor-induced gamma-aminobutyric acid release in central amygdala affected by, 666
 - early life adversity and, 182
 - heroin
 - deep brain stimulation for, e35
 - dopamine D2 receptor binding deficits in, 192
 - hypocretin/orexin signaling in, 214
 - nicotine. *See* Nicotine
- Adenylate cyclase 7
 - depression and, 627
- Adenylyl cyclases
 - emotionality and, 572
- Adolescents
 - cannabis use in, orbitofrontal volumes as predictor of, 684
 - circadian-relevant reward circuitry activity in, *PER2 rs2304672* polymorphism modulation of, 451
 - depression in, fronto-striato-cerebellar dysregulation in, 59
 - drug use by, 664
- Affective disorders
 - adenylate cyclase 7's role in biology of, 627
- Aggression
 - optogenetics studies of, 1081
- Aging
 - cellular, hostility and, 767
 - cholinergic aspects of, 760
- Alcohol
 - chronic exposure to
 - delta opioid receptor emergence after, 232
 - nociceptin/orphanin FQ blockade of corticotropin-releasing factor-induced gamma-aminobutyric acid release in central amygdala affected by, 666
 - cortical γ -aminobutyric acid levels reduced by, 239
 - N*-acetylaspartate levels reduced by, 239
- Alcoholism
 - cortico-striatal-midbrain activation synchrony effects on inhibitory control and conflict processing in men recovering from, 269
 - delta opioid receptors emergence in, 232
 - frontal white matter integrity as predictor of treatment outcome, 262
- Alzheimer's disease
 - asymmetric loss of parietal activity as cause of spatial bias in, 798
 - basal forebrain cholinergic system atrophy in, 805
 - cerebral hypometabolism in, 792
 - cholinergic aspects of, 760, 805
 - double-stranded RNA-dependent protein kinase in, cerebrospinal fluid levels of, 829
 - Down syndrome and, 403
 - hypometabolism in, 792
 - mild cognitive impairment progression to, 814
- Amino acid neurotransmitter metabolism
 - ketamine effects on, ^1H -[^{13}C]-nuclear magnetic spectroscopy measures of, 1015
- Amygdala
 - abnormalities of, in schizophrenia, 136
 - corticotropin-releasing factor, site-specific genetic manipulation of, 317
 - excitatory processes in, 335
 - fear learning in, 335
 - nociceptin/orphanin FQ blockade of corticotropin-releasing factor-induced gamma-aminobutyric acid release in, chronic ethanol exposure effects on, 666
- Amyloid deposition with temporal delay
 - cerebral hypometabolism in Alzheimer's disease after, 792
- Amyloid precursor protein
 - Alzheimer's disease and, 403
- Anabolic-androgenic steroid abuse
 - risk factors for, in male weightlifters, 254
- Angiotensin II
 - hypertension caused by, 774
- Anorexia nervosa
 - food representation in, e31, e33
- Anterior cingulate cortex
 - reduced activation of, associated with prefrontal-temporal cortex thinning in schizophrenia, 146
- Antidepressants
 - heart rate variability effects, e27, e29
 - ketamine's effects as, in bipolar disorder, 939
- Antipsychotic drugs
 - brain volume affected by, 855
- Antisocial personality disorder
 - DSM-IV criteria for, 247
 - substance dependence comorbidity with, *COL25A1* association with, 733
- Anxiety
 - cholinergic transmission in, 75
 - early-life forebrain glucocorticoid receptor overexpression and, 224
 - emotional word encoding and recognition in, 593
 - leukocyte transcriptional dynamics, cognitive-behavioral stress management effects on, 366
 - p75NTR's role in, 75
- Arousal
 - optogenetic studies of, 1046
- Attention
 - biased, 373
 - in schizophrenia, 162
- Attention-deficit/hyperactivity disorder
 - brain-behavior relationships in, 434
 - functional connectivity abnormalities in, 443
 - inattention associated with, 443
 - perinatal risk factors, 474
 - working memory impairments in, stimulant effects on, 458
- Auditory mismatch negativity
 - in schizophrenia, 969
- Autism
 - behavioral disturbances associated with, *N*-acetylcysteine used to treat, 956
 - candidate genes, 410
 - irritability associated with, *N*-acetylcysteine used to treat, 956
 - transcription factor specificity protein 1 levels in, 410

- Autism spectrum disorders
 - copy number variations in, 392
 - social impairments in, mirror neuron activity associated with, 427
- Aversion
 - bed nucleus of stria terminalis catecholamines response to, 327
- Backward masking
 - in schizophrenia, 162
- β -Arrestin2
 - cannabinoid CB1 receptor signaling and adaptation regulated by, 714
- Basal forebrain cholinergic nuclei
 - in Alzheimer's disease, 760, 805
- Bed nucleus of stria terminalis
 - catecholamines in, reward and aversion effects on, 327
 - presynaptic inhibition of gamma-aminobutyric acid release in, by kappa opioid receptor signaling, 725
- Biased attention
 - variations in, for emotional information, 373
- Biomarkers
 - in acute myocardial infarction, 22
- Bipolar affective disorder
 - MAG1* copy number variation in, 922
- Bipolar disorder
 - cortical volume, surface area, and thickness in, 552
 - euthymia in, 570
 - facial emotion processing in, neural activation during, 603
 - ketamine use in, 939
 - metal ions transporter and, 169
 - neocortical synaptic plasticity impairments in, 68
 - schizophrenia and, comparisons between, 881
 - SLC39A8* and, 169
- Body-image disorders
 - anabolic-androgenic steroid abuse risks, 254
- Brain circuits
 - studies of, 1028
- Brain-derived neurotrophic factor
 - depression and, 30
 - promotor IV, depression and, 618
 - Val66Met allele, basal and ketamine-stimulated synaptogenesis in prefrontal cortex impaired by, 996
- Brain volume
 - haloperidol effects on, 855
 - lithium effects on, 855
 - schizophrenia and, genetic and environmental determinants of association between, 915
- Candidate genes
 - autism, 410
- Cannabinoid 1 receptor messenger RNA
 - cortical glutamic acid decarboxylase 67 deficiency effects on, 114
- Cannabinoid CB1 receptor signaling
 - β -arrestin2 regulation of, 714
- Cannabinoids
 - psychosis and, 662
 - working memory affected by, 662, 693
- Cannabis
 - adolescent use of, orbitofrontal volumes as predictor of, 684
 - dopamine release in users of, 677
- Cardiovascular risk
 - antidepressants effect on, e27, e29
- Catecholamines
 - bed nucleus of stria terminalis, reward and aversion effects on, 327
- Catechol-O-methyltransferase inhibition
 - cognitive effects produced by, *COMT* Val158Met polymorphism as determinant of, 538
- Cell cycle
 - schizophrenia-related alterations in, 129
- Cellular aging
 - hostility and, 767
- Cerebellar damage
 - behavioral effects of, e41
- Cerebrospinal fluid
 - double-stranded RNA-dependent protein kinase levels, in Alzheimer's disease, 829
- Child abuse
 - psychiatric illness and, correlation between, 280
- Childhood maltreatment
 - depression risks, 286
 - MAOA* interactions with, effect on mental health outcomes, 350
 - posttraumatic stress disorder risks, 286
- Cholinergic transmission
 - in anxiety, 75
- Chronic electroconvulsive therapy
 - cyclic adenosine monophosphate response element binding protein levels affected by, 51
- Chronic ethanol exposure
 - delta opioid receptor emergence after, 232
 - nociceptin/orphanin FQ blockade of corticotropin-releasing factor-induced gamma-aminobutyric acid release in central amygdala affected by, 666
- Circadian-relevant reward circuitry activity
 - PER2 rs2304672* polymorphism of, in adolescents, 451
- Cocaine
 - rewarding effects of, Δ FosB effects on, 44
 - synaptic potentiation in ventral tegmental area induced by, protein kinase M ζ necessary for, 706
- Cocaine hydrolase
 - viral transfer of, blockade of reinstatement of cocaine seeking secondary to, 700
- Cocaine seeking
 - cocaine hydrolase blockade of reinstatement of, 700
 - N*-acetylcysteine effects on relapse to, 978
- Cocaine sensitization
 - early-life forebrain glucocorticoid receptor overexpression and, 224
- Cognition
 - catechol-O-methyltransferase inhibition effects on, *COMT* Val158Met polymorphism as determinant of, 538
- Cognitive impairment
 - mild. *See* Mild cognitive impairment
 - in psychiatric illness, 487
 - in schizophrenia
 - description of, 890
 - N*-methyl-D-aspartate receptor hypofunction associated with, 987
- Cognitive lifestyle
 - dementia and, 783
- Cognitive reserve, 765
- Cognitive-behavioral stress management
 - anxiety-related leukocyte transcriptional dynamics reversed by, 366
- COL25A1*
 - comorbid antisocial personality disorder and substance dependence associated with, 733
- COMT* Val158Met polymorphism
 - catechol-O-methyltransferase inhibition-related cognitive effects determined by, 538

Download English Version:

<https://daneshyari.com/en/article/4177896>

Download Persian Version:

<https://daneshyari.com/article/4177896>

[Daneshyari.com](https://daneshyari.com)